Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
BELGRADE, Mont., Nov. 09, 2017 -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November 9, 2017.
The Company now plans to release its third quarter 2017 financial results in conjunction with the filing of its 10-Q which is currently expected to occur by November 20, 2017.
About Xtant Medical
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Investor Contact
CG CAPITAL
Rich Cockrell
877.889.1972
[email protected]
Company Contact
Xtant Medical
Molly Mason
[email protected]
